EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer

Xinwen Wang iD, Min Wang, Qijun Lin, Lixin He, Baolin Zhang, Xin Chen, Guanhong Chen, Hong Du, Chuandong Lang, Xinsheng Peng, Yuhu Dai iD

Advanced Science · 2025-01 · 12 (2)

DOI: 10.1002/advs.202407662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.11.2024. Verfasst von Xinwen Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Osteoblasts, Drug Resistance, Neoplasm, Extracellular Matrix Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Scientific Research Foundation of Education Department of Anhui Province of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS1), which activates the downstream mitogen‐activated protein kinase (MAPK) signaling pathway to induce anti‐androgen resistance. Furthermore, inhibiting ECM1 or utilizing the ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores tumor cell sensitivity to ENZ. Taken together, a potential mechanism is identified through which osteoblast‐derived ECM1 drives resistance in bone metastatic prostate cancer under ENZ treatment. Additionally, the findings indicate that ECM1 and ENO1 may serve as potential targets for developing therapies for bone metastatic castration‐resistant prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsOsteoblastsDrug Resistance, NeoplasmExtracellular Matrix ProteinsProstatic NeoplasmsAndrogen AntagonistsMaleHumansCell Line, TumorNitrilesBenzamidesPhenylthiohydantoinAnimalsCell ProliferationMice

Stichwörter der Autor:innen

ECM1ENO1enzalutamide resistanceosteoblastprostate cancer

Substanzen

Extracellular Matrix ProteinsNitrilesAndrogen AntagonistsenzalutamideBenzamidesPhenylthiohydantoin

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
  • Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, 510080, China.
  • Department of Pathology, Guangzhou First People's Hospital, Guangzhou, 510080, China.
  • Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.

ORCID-Profile: Xinwen Wang, Yuhu Dai

Förderung

  • China Postdoctoral Science Foundation
  • Scientific Research Foundation of Education Department of Anhui Province of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • State-funded Postdoctoral Researchers Plan

Zitieren

APA

Wang, X., Wang, M., Lin, Q., He, L., Zhang, B., Chen, X., Chen, G., Du, H., Lang, C., Peng, X., & Dai, Y. (2025). Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer. Advanced Science, 12(2). https://doi.org/10.1002/advs.202407662

Vancouver

Wang X, Wang M, Lin Q, He L, Zhang B, Chen X, et al. Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer. Advanced Science. 2025;12(2). doi:10.1002/advs.202407662

BibTeX
@article{Wang2025,
  author = {Wang, Xinwen and Wang, Min and Lin, Qijun and He, Lixin and Zhang, Baolin and Chen, Xin and Chen, Guanhong and Du, Hong and Lang, Chuandong and Peng, Xinsheng and Dai, Yuhu},
  title = {Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {2},
  doi = {10.1002/advs.202407662}
}
Kostenlos starten →